Get the Stockscreener App
4.01
1.01%
0.04
After Hours:
4.05
0.04
+1.00%
Lantern Pharma Inc stock is traded at $4.01, with a volume of 32,315.
It is up +1.01% in the last 24 hours and down -7.82% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.97
Open:
$3.93
24h Volume:
32,315
Relative Volume:
0.21
Market Cap:
$43.31M
Revenue:
-
Net Income/Loss:
$-19.25M
P/E Ratio:
-2.2528
EPS:
-1.78
Net Cash Flow:
$-17.87M
1W Performance:
-1.72%
1M Performance:
-7.82%
6M Performance:
+13.92%
1Y Performance:
+28.32%
1-Day Range:
$3.85
$4.09
1-Week Range:
$3.75
$4.28
52-Week Range:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
4.01 | 42.87M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
How Lantern Pharma Inc. stock reacts to oil pricesWeekly Profit Report & AI Based Buy and Sell Signals - newser.com
What drives Lantern Pharma Inc stock priceEvening Star Patterns & Big Gains Small Budget - earlytimes.in
Is Lantern Pharma Inc. stock attractive for income investorsQuarterly Profit Summary & Short-Term Trading Alerts - newser.com
Using economic indicators to assess Lantern Pharma Inc. potentialJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pocono Record
Full technical analysis of Lantern Pharma Inc. stock2025 Valuation Update & Weekly Breakout Watchlists - newser.com
Will Lantern Pharma Inc. stock maintain dividend yield2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Lantern Pharma Inc. stock trendline breakdownTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
How to interpret RSI for Lantern Pharma Inc. stockJuly 2025 Momentum & Reliable Intraday Trade Plans - newser.com
Will Lantern Pharma Inc. stock recover after recent dropMarket Movers & Advanced Swing Trade Entry Plans - newser.com
Why Lantern Pharma Inc. stock is favored by pension fundsJuly 2025 Opening Moves & Stock Market Timing Techniques - newser.com
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT - MarketScreener
Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP) - MarketScreener
Is Lantern Pharma Inc. stock a buy before product launchesOil Prices & Free Technical Confirmation Trade Alerts - newser.com
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - BioSpace
Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress - Digital Journal
Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results fo - GuruFocus
Lantern Pharma presents LP-284 clinical data at 25th LL&M Congress - MarketScreener
What technical signals suggest for Lantern Pharma Inc. stockGDP Growth & Growth Focused Stock Pick Reports - fcp.pa.gov.br
Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks
Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
When is the best time to exit Lantern Pharma Inc.July 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - newser.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - BioSpace
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):